SBIR Phase 1 grant, NHLBI, NIH (Apr 2018)

We proudly announce that TeraImmune was granted an SBIR Phase 1 grant from NHLBI, NIH on 3/29/2018. The project title is 'Factor VIII (fVIII)-specific therapeutic Tregs and related cGMP manufacturing process for hemophilia A patients with inhibitors'.